Adolfsson J
Department of Urology, Karolinska Hospital, Stockholm, Sweden.
J Urol. 1993 Feb;149(2):326-8; discussion 328-9. doi: 10.1016/s0022-5347(17)36071-8.
Fifty patients with extracapsular prostate cancer without known distant metastases were included in a protocol of surveillance followed by deferred treatment of progression. The median observed followup time was 78 months. The risk of developing distant metastases, if not dying before, was 24% and 37% at 5 and 9 years, respectively. The risk of dying of prostate cancer, if not dying of other diseases before, was 12% and 30% at 5 and 9 years, respectively. Thus, the cancer specific survival was 88% at 5 years and 70% at 9 years.
五十例患有包膜外前列腺癌且无已知远处转移的患者被纳入一项监测方案，随后对病情进展进行延期治疗。观察到的中位随访时间为78个月。若未在之前死亡，发生远处转移的风险在5年和9年时分别为24%和37%。若未在之前死于其他疾病，死于前列腺癌的风险在5年和9年时分别为12%和30%。因此，癌症特异性生存率在5年时为88%，在9年时为70%。
